Page 216 - HIV/AIDS Guidelines
P. 216

HIV in the genital and blood compartments and, hence, the inability to transmit HIV to others. 41-42

            Maximal suppression of viremia not only depends on the potency of the ARV regimen used but also on the
            patient’s adherence to prescribed therapy. Suboptimal adherence can lead to viremia that not only harms the
            patient but also increases his/her risk of transmitting HIV (including drug-resistant strains) via sex or needle
            sharing. Screening for and treating behavioral conditions that can impact adherence, such as depression and
            alcohol and substance use, improve overall health and reduce the risk of secondary transmission.


            Summary
            Consistent and effective use of ART resulting in a sustained reduction in viral load in conjunction with
            consistent condom usage, safer sex and drug use practices, and detection and treatment of STDs are essential
            tools for prevention of sexual and blood-borne transmission of HIV. Given these important considerations,
            medical visits provide a vital opportunity to reinforce HIV prevention messages, discuss sex- and drug-
            related risk behaviors, diagnose and treat intercurrent STDs, review the importance of medication adherence,
            and foster open communication between provider and patient.


            References

            1.  Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One.
               2011;6(8):e17502.

            2.  Centers for Disease Control and Prevention. HIV Surveillance Report
               http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. 2009. Published February 2011. Accessed December 7,
               2011.
            3.  Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med.
               Aug 11 2011;365(6):493-505.
            4.  Mayer KH, Safren SA, Gordon CM. HIV care providers and prevention: opportunities and challenges. J Acquir Immune
               Defic Syndr. Oct 1 2004;37(Suppl 2):S130-132.
            5.  Morin SF, Koester KA, Steward WT, et al. Missed opportunities: prevention with HIV-infected patients in clinical care
               settings. J Acquir Immune Defic Syndr. Aug 1 2004;36(4):960-966.
            6.  Metsch LR, McCoy CB, Miles CC, Wohler B. Prevention myths and HIV risk reduction by active drug users. AIDS Educ
               Prev. Apr 2004;16(2):150-159.
            7.  Johnson WD, Diaz RM, Flanders WD, et al. Behavioral interventions to reduce risk for sexual transmission of HIV
               among men who have sex with men. Cochrane Database Syst Rev. 2008(3):CD001230.
            8.  Centers for Disease Control and Prevention (CDC). Evolution of HIV/AIDS prevention programs—United States, 1981-
               2006. MMWR Morb Mortal Wkly Rep. Jun 2 2006;55(21):597-603.
            9.  Gorbach PM, Drumright LN, Daar ES, Little SJ. Transmission behaviors of recently HIV-infected men who have sex
               with men. J Acquir Immune Defic Syndr. May 2006;42(1):80-85.
            10. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. Dec 17
               2010;59(RR-12):1-110.
            11. Tanton C, Weiss HA, Le Goff J, et al. Correlates of HIV-1 genital shedding in Tanzanian women. PLoS One.
               2011;6(3):e17480.
            12. Wright TC, Jr., Subbarao S, Ellerbrock TV, et al. Human immunodeficiency virus 1 expression in the female genital tract
               in association with cervical inflammation and ulceration. Am J Obstet Gynecol. Feb 2001;184(3):279-285.

            13. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes
               simplex virus lesions in HIV-1-infected men. JAMA. Jul 1 1998;280(1):61-66.



            Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents          L-3

                            Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.
   211   212   213   214   215   216   217   218   219   220   221